Viela Bio Announces Pricing of Initial Public Offering
October 02 2019 - 9:54PM
Viela Bio, Inc., a clinical-stage biotechnology company pioneering
treatments for autoimmune and severe inflammatory diseases, today
announced the pricing of its initial public offering
of 7,900,000 shares of its common stock at a price to the
public of $19.00 per share. The gross proceeds to Viela Bio from
the offering, before deducting the underwriting discounts and
commissions and offering expenses, are expected to be approximately
$150 million. The shares are expected to begin trading on the
Nasdaq Global Select Market on October 3, 2019 under the symbol
“VIE.” The offering is expected to close on October 7, 2019,
subject to customary closing conditions. In addition, Viela Bio has
granted the underwriters a 30-day option to purchase up to an
additional 1,185,000 shares of common stock at the initial
price to the public less underwriting discounts.
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and
Cowen and Company, LLC are acting as the joint book-running
managers for this offering. Guggenheim Securities, LLC is acting as
lead manager for this offering.
The offering will be made only by means of a prospectus. Copies
of the final prospectus related to the offering, when available,
may be obtained from:
- Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY 10282,
email: prospectus-ny@ny.email.gs.com, telephone:
1-866-471-2526, fax: 1-212-902-9316;
- Morgan Stanley & Co. LLC, Attention: Prospectus Department,
180 Varick Street, Second Floor, New York, NY 10014; or
- Cowen and Company, LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, email: PostSaleManualRequests@broadridge.com,
telephone: 1-833-297-2926.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on October 2, 2019. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Viela BioViela Bio, headquartered in
Gaithersburg, Maryland, is a clinical-stage biotechnology company
pioneering treatments for autoimmune and severe inflammatory
diseases.
Contacts
Investors:Solebury TroutChad
Rubin646-378-2947crubin@soleburytrout.com
Media: Solebury Trout Amy Bonanno 914-450-0349
abonanno@soleburytrout.com
Viela Bio (NASDAQ:VIE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viela Bio (NASDAQ:VIE)
Historical Stock Chart
From Apr 2023 to Apr 2024